Accelerating Drug Discovery for Frontotemporal Degeneration (ADDF/AFTD RFP)

About this program

The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) are jointly funding research to accelerate drug discovery for frontotemporal dementia (FTD), focusing on innovative small molecule and biologic development programs. Funding priorities include lead optimization, in vivo testing, and IND-enabling studies, targeting areas such as autophagy, epigenetics, and neuroprotection. Applicants must demonstrate a strong scientific approach, feasibility, and a clear biological connection to FTD, with average awards ranging from $300,000 to $350,000 and potential for follow-on funding. Eligibility is open to researchers and clinicians worldwide, including academic, nonprofit, and biotechnology institutions, with industry partnerships encouraged and biotechnology companies required to justify the need for nonprofit funding.